Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD trial) - ZENITH-CKD

Study identifier:D4325C00001

ClinicalTrials.gov identifier:NCT04724837

EudraCT identifier:2020-004101-32

CTIS identifier:N/A

Study Complete

Official Title

A Phase 2b Multicentre, Randomised, Double-Blind, Active-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) ≥ 20 mL/min/1.73 m^2

Medical condition

Chronic Kidney Disease

Phase

Phase 2

Healthy volunteers

No

Study drug

Zibotentan, Dapagliflozin, Placebo

Sex

All

Actual Enrollment

542

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 28 Apr 2021
Primary Completion Date: 01 Jun 2023
Study Completion Date: 01 Jun 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria